# FDA Approves Ekterly (Sebetralstat) for Hereditary Angioedema Acute Attacks

> fda · REPORTED · 2025-07-01

The FDA approved Ekterly (sebetralstat) from KalVista Pharmaceuticals in July 2025 as an oral treatment for acute attacks of hereditary angioedema, adding a new on-demand therapy option for patients with this rare genetic disorder.

- Company: KalVista Pharmaceuticals
- Sector: therapeutics
- Primary source: https://acapharma.net/new-items/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.